Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
38 Cards in this Set
- Front
- Back
|
phenelzine (Nardil) |
type: antidepressant - MAOI inhibitor
mechanism of action: Monoamine Oxidase A inhibitor - i.e. inhibits degradation of NE, DA, and 5-HT |
|
|
imipramine (Tofranil) |
type: antidepressant - tricyclic
mechanism of action: inhibit reuptake (transporters) of NE and 5-HT |
|
|
amitriptyline (Elavil) |
type: antidepressant - tricyclic
mechanism of action: inhibit reuptake (transporters) of NE and 5-HT |
|
|
fluoxetine (Prozac) |
type: antidepressant - SSRI
mechanism of action: inhibit reuptake (transporters) of 5-HT selectively |
|
|
sertraline (Zoloft) |
type: antidepressant - SSRI
mechanism of action: inhibit reuptake (transporters) of 5-HT selectively |
|
|
paroxetine (Paxil) |
type: antidepressant - SSRI
mechanism of action: inhibit reuptake (transporters) of 5-HT selectively |
|
|
citalopram (Celexa) |
type: antidepressant - SSRI
mechanism of action: inhibit reuptake (transporters) of 5-HT selectively |
|
|
buproprion (Wellbutrin, Zyban) |
type: antidepressant - atypical - DSRI
mechanism of action: inhibit reuptake (trasporters) of DA selectively |
|
|
atomoxetine (Strattera) |
type: antidepressant - atypical - NSRI
mechanism of action: inhibit reuptake (transporters) of NE selectively |
|
|
lithium |
type: anti-manic
mechanism of action: inhibition of signal transduction by phosphoinositide pathway (may be linked) |
|
|
carbamazepine (Tegretol) |
type: anti-manic
mechanism of action: inhibits reuptake (transporters) of NE, and acutely blocks adenosine receptors and up regulates w/ chronic use |
|
|
chlorpromazine (Thorazine) |
type: traditional antipsychotic
mechanism of action: block dopamine D2 receptor for antipsychotic/therapeutic effects (additionally block H1, muscarinic, a1, 5-HT2) |
|
|
haloperidol (Haldol) |
type: traditional antipsychotic
mechanism of action: block dopamine D2 receptor for antipsychotic/therapeutic effects (additionally block H1, muscarinic, a1, 5-HT2) |
|
|
reserpine |
type: traditional antipsychotic (?)
mechanism of action: inhibition of monoamines (NE, DA, 5-HT) via inhibition of VMAT - vesicular monoamine transporter |
|
|
clozapine (Clorazil) |
type: atypical antipsychotic
mechanism of actions: weaker affinity at D2, stronger affinity at D4 and 5-HT2A; blockade of receptors, inhibtion |
|
|
risperidone (Risperdal) |
type: atypical antipsychotic
mechanism of actions: weaker affinity at D2, stronger affinity at D4 and 5-HT2A; blockade of receptors, inhibtion |
|
|
quetiapine (Seroquel) |
type: atypical antipsychotic
mechanism of actions: weaker affinity at D2, strongest affinity at a1 receptor, also at 5-HT2, music, and H1 receptors; blockade of receptors, inhibition |
|
|
aripiprazole (Abilify) |
type: atypical antipsychotic - DA system stabilizer
mechanism of action: DA partial agonist, high affinity for D2 receptors |
|
|
lysergic acid diethylamide |
type: serotonergic hallucinogen - synthetic
mechanism of action: 5-HT receptor agonist, targeting 5-HT2A receptors ; enhance 5-HT neuron and enhance cortical glutamate by stimulating raphe nuclei that communicate w/ cortical pyramidal neurons |
|
|
psilocybin, psilocin |
type: serotonergic hallucinogen - natural - shrooms
mechanism of action: 5-HT receptor agonist, targeting 5-HT2A receptors ; enhance 5-HT neuron and enhance cortical glutamate by stimulating raphe nuclei that communicate w/ cortical pyramidal neurons |
|
|
dimethyltryptamine |
type: serotonergic hallucinogen
mechanism of action: 5-HT receptor agonist, targeting 5-HT2A receptors ; enhance 5-HT neuron and enhance cortical glutamate by stimulating raphe nuclei that communicate w/ cortical pyramidal neurons |
|
|
phencyclidine (PCP) |
type: dissociative hallucinogen/anesthetic
mechanism of action: inhibition of NMDA receptors by binding to site w/in channel, below Mg2+ block |
|
|
ketamine |
type: dissociative hallucinogen/anesthetic
mechanism of action: inhibition of NMDA receptors by binding to site w/in channel, below Mg2+ block |
|
|
tetrahydrocannabinoid, cannbinol |
type: cannabinoid - hallucinogen
mechanism of action: CB2 receptor agonists; presynaptic inhibition through metabotropic inhibition of cAMP and subsequent inhibition of Ca2+ - decreases amount of neurotransmitter release |
|
|
muscimol |
type: depressant
mechanism of action: GABAa receptor agonist at GABA binding site |
|
|
picrotoxin |
type: convulsant
mechanism of action: GABAa receptor antagonist at neuropeptide (?) binding site w/in chloride channel; inhibition of GABA function |
|
|
ethanol |
type: alcohol
mechanism of action: NMDA receptor antagonism; GABAa receptor enhancement; increase in mesolimbic DA firing; increase in endogenous opioid synthesis/release |
|
|
methanol |
type: alcohol
mechanism of action: blindness and death by liver metabolite formic acid |
|
|
disulfiram (Antabuse) |
type: enzyme inhibitor - alcoholism dependence treatment
mechanism of action: inhibition of acetaldehyde dehydrogenase, thus build up of toxic acetaldehyde |
|
|
thiopental |
type: barbiturate - short acting - anesthetic
mechanism of action: GABAa receptor agonist at barbiturate binding site - increase GABAa affinity for GABA (increases duration of time of opening) and directly opens chloride channel; enhancement of GABA-ergic effect thus enhancement of inhibition |
|
|
secobarbital |
type: barbiturate - intermediate acting
mechanism of action: GABAa receptor agonist at barbiturate binding site - increase GABAa affinity for GABA (increases duration of time of opening) and directly opens chloride channel; enhancement of GABA-ergic effect thus enhancement of inhibition |
|
|
phenobarbital |
type: barbiturate - long acting - anti-convulsant (epilepsy treatment)
mechanism of action: GABAa receptor agonist at barbiturate binding site - increase GABAa affinity for GABA (increases duration of time of opening) and directly opens chloride channel; enhancement of GABA-ergic effect thus enhancement of inhibition |
|
|
alprazolam (Xanax) |
type: benzodiazepine - short acting
mechanism of action: GABAa receptor enhancement by binding at benzodiazepine binding site - increases GABAa affinity for GABA (increases number of channel openings); enhancement of GABA-ergic effect thus enhancement of inhibition |
|
|
lorazepam (Ativan) |
type: benzodiazepine - intermediate acting
mechanism of action: GABAa receptor enhancement by binding at benzodiazepine binding site - increases GABAa affinity for GABA (increases number of channel openings); enhancement of GABA-ergic effect thus enhancement of inhibition |
|
|
diazepam (Valium) |
type: benzodiazepine - long acting
mechanism of action: GABAa receptor enhancement by binding at benzodiazepine binding site - increases GABAa affinity for GABA (increases number of channel openings); enhancement of GABA-ergic effect thus enhancement of inhibition |
|
|
gamma hydroxybutyrate (GHB) |
type: predatory depressant
mechanism of action: weak GABA agonist; acts on GABAa and GHB receptors to produce inhibition |
|
|
flunitrazepam (Rohypnol) |
type: predatory depressant - barbiturate
mechanism of action: GABAa receptor enhancement by binding at benzodiazepine binding site - increases GABAa affinity for GABA (increases number of channel openings); enhancement of GABA-ergic effect thus enhancement of inhibition |
|
|
buspirone (Buspar) |
type: antidepressant / anxiolytic - atypical
mechanism of action: partial 5-HT1A agonist |
